Survival and Side Effects of Cisplatin/Cyclophosphamide and Carboplatin/Paclitaxel Adjuvant Chemotherapy in Stage IC-IV Ovarian Cancer

  • Unedo H Markus Obstetrics and Gynecology Department Faculty of Medicine, University of Indonesia
  • Hariyono Winarto Obstetrics and Gynecology Department Faculty of Medicine, University of Indonesia
  • Andrijono Andrijono Obstetrics and Gynecology Department Faculty of Medicine, University of Indonesia
  • Bambang Sutrisna Faculty of Public Health, University of Indonesia

Abstract

Objective: To compare the survival and side effects in epithelial ovarian cancer patients receiving adjuvant chemotherapy of cisplatin/ cyclophosphamide and carboplatin/paclitaxel. Method: We recruited epithelial ovarian cancer patients receiving cisplatin/cyclophosphamide (group A) or carboplatin/paclitaxel (group B) adjuvant chemotherapy after surgery. Chemotherapy was given for six cycles. Overall survival and side effects were assessed. Result: A total of 49 patients were recruited, consisting of 25 patients for group A and 24 patients for group B. In this study, the overall survival of stage IC-IV ovarian cancer patients was 37.3 months in group A (95%CI=31.86-43.46) and 35.5 months (95%CI= 13.93- 43.46) in group B (p<0.001). Hematologic side effects of both groups were not significantly different, i.e: leukopenia 12% vs 18% (p=0.14) and thrombocytopenia 5.3% vs 9.7% (p=0.38) in group A and group B, respectively. Gastrointestinal toxicity occurred more frequently in group A, i.e: nausea 38.6% vs 22.9% (p<0.05), vomitus 24.6% vs 11.8% (p<0.05) in group A and group B, respectively. Symptoms of peripheral sensory neuropathy were found in 5.33% of group A subjects and 23.6% of group B (p<0.05). Conclusion: Overall survival in this study is better in patients receiving cisplatin/cyclophosphamide than patients receiving carboplatin/ paclitaxel. However, further study with larger sample is still needed. The gastrointestinal side effects are found more frequently in the cisplatin/cyclophosphamide group, while peripheral sensory neuropathy and hematologic side effects are more frequent in the carboplatin/paclitaxel group. Keywords: carboplatin/paclitaxel, cisplatin/cyclophosphamide, ovarian cancer, overall survival, side effects

Downloads

Download data is not yet available.

Author Biographies

Unedo H Markus, Obstetrics and Gynecology Department Faculty of Medicine, University of Indonesia
Gynecologic Oncology Division
Hariyono Winarto, Obstetrics and Gynecology Department Faculty of Medicine, University of Indonesia
Gynecologic Oncology Division
Andrijono Andrijono, Obstetrics and Gynecology Department Faculty of Medicine, University of Indonesia
Gynecologic Oncology Division
Bambang Sutrisna, Faculty of Public Health, University of Indonesia
Epidemiology Department
Published
2015-04-21
Section
Research Article